

Date: 25th January, 2024

To,
BSE Limited
P. J. Towers, Dalal Street, Fort
Mumbai – 400 001

Ref.: BSE Scrip Code No. “533138”

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra - Kurla Complex,
Bandra (East), Mumbai – 400 051

Ref.: “ASTEC”

Debt Segment NSE:
NCD-ASTEC-ISIN: INE563J08015

Sub.: Outcome of the Board Meeting

Pursuant to Regulations 30, 33, 51 and 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) read with Schedule III to the Listing Regulations, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e., on **Thursday, 25th January, 2024** (which commenced at 3.00 p.m. and concluded at 4.32 p.m.), *inter alia*, has approved / noted the following:

(a) APPROVAL OF THE UNAUDITED FINANCIAL RESULTS (STANDALONE AND CONSOLIDATED) FOR THE QUARTER AND NINE MONTHS’ PERIOD ENDED 31ST DECEMBER, 2023:

Upon recommendation of the Audit Committee, the Board of Directors has approved the Unaudited Financial Results (Standalone & Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter and Nine Months’ period ended 31st December, 2023 (enclosed herewith).

(b) NOTING OF THE STATUTORY AUDITORS’ LIMITED REVIEW REPORTS ON THE UNAUDITED FINANCIAL RESULTS (STANDALONE & CONSOLIDATED) FOR THE QUARTER AND NINE MONTHS’ PERIOD ENDED 31ST DECEMBER, 2023:

The Board of Directors took note of the Limited Review Reports of the Statutory Auditors on the Unaudited Financial Results (Standalone & Consolidated) for the Quarter and Nine Months’ period ended 31st December, 2023 (enclosed herewith).

The Limited Review Reports of the Statutory Auditors are with unmodified opinion with respect to the Unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Nine Months’ period ended 31st December, 2023.

(c) RE-APPOINTMENT OF MR. ANURAG ROY (DIN: 07444595) AS THE “WHOLE-TIME DIRECTOR & CHIEF EXECUTIVE OFFICER” FOR A FURTHER TERM OF 3 (THREE) YEARS WITH EFFECT FROM 28TH JULY, 2024 UPTO 27TH JULY, 2027, SUBJECT TO THE APPROVAL OF SHAREHOLDERS:

The Board of Directors of the Company, based on the recommendation of the Nomination and Remuneration Committee of the Board of Directors, has re-appointed Mr. Anurag Roy [Director Identification Number (DIN): 07444595] as the “Whole Time Director & Chief Executive Officer” for a term of 3 (Three) years with effect from 28th July, 2024 upto 27th July, 2027 and approved the remuneration payable to him in such capacity. The re-appointment of Mr. Anurag Roy as the “Whole Time Director & Chief Executive Officer” for a term of 3 (Three) years with effect from 28th July, 2024 upto 27th July, 2027 is subject to approval of the Shareholders of the Company.

Further, Mr. Anurag Roy is not related to any of the Promoters, Members of the Promoter Group and Directors of the Company and is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India (SEBI) or any other such authority.

Disclosure required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A of Part A of Schedule III to the said Regulations, with regard to change in Directors and Key Managerial Personnel is given hereunder:

Sr No.	Disclosure Requirement	Details
1	Reason for Change viz. appointment, resignation, removal, death or otherwise	Re-appointment of Mr. Anurag Roy (DIN: 07444595) as "Whole Time Director & Chief Executive Officer", subject to approval of the Shareholders
2	Date of Appointment / Cessation (as applicable) & term of Appointment	Re-appointment for a term of 3 (Three) years with effect from 28 th July, 2024, i.e., upto 27 th July, 2027
3	Brief Profile	<p>Mr. Anurag Roy is a B. Tech from HBTI, Kanpur. He completed his Masters in International Business from IIFT and also did his Executive MBA from Columbia Business School, New York, USA. Mr. Anurag has 24+ years' experience working in leading pharmaceuticals/chemicals companies such as DSM, Dr. Reddy's Labs, BASF and Jubilant Life Sciences. He has proven track record of delivering commercial and operational excellence and leading several manufacturing, supply sites and CMOS.</p> <p>Mr. Anurag Roy joined the Company in July 2021 from Navin Fluorine International Ltd. / Manchester Organics wherein he was working as COO-CRAMS, Pharmaceuticals. He was responsible for P&L to manage and grow the global contract development & manufacturing business with global footprints (UK, Japan, USA) and GMP manufacturing in India. He was also responsible for building the customer base and global teams and introduce newer technology / capability enhancement by setting in-house capabilities or CMOs to cater to drug development pipelines of innovators.</p> <p>At Astec LifeSciences Limited, the primary contributions of Mr. Anurag Roy are in scaling the existing CDMO business and in building institutional capabilities for two herbicide plants and the Research & Development (R&D) Centre.</p>
4	Disclosure of Relationships between Directors (in case of Appointment of a Director)	Mr. Anurag Roy is not related to any of the Promoters, Members of the Promoter Group and Directors of the Company and is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India (SEBI) or any other such authority.

The Board considered and approved seeking approval of the Shareholders by way of Postal Ballot for re-appointment of Mr. Anurag Roy as “Whole Time Director & Chief Executive Officer” of the Company as mentioned in item no. (c) above.

Please take the above information on your records.

Thanking you,

Yours sincerely,

For Astec LifeSciences Limited

TEJASHREE

ROHAN PRADHAN

Tejashree Pradhan

Company Secretary & Compliance Officer

(FCS 7167)

Encl.: As above

Digitaly signed by TEJASHREE ROHAN PRADHAN
DN: c=IN, o=MAHARASHTRA, ou=TEJASHREE ROHAN PRADHAN, email=TEJASHREE.ROHAN.PRADHAN@ASTEC.LIFE, cn=TEJASHREE ROHAN PRADHAN
Date: 2024.07.15 16:37:01 +05'30'

Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecls.com, **Tel no.:** 022-2519 5768, **Fax no.:** 022-2261 8289, **Email id:** astecinvestors@godrejastec.com

Statement of Unaudited Standalone Financial Results for the Quarter and Nine Months ended 31st December, 2023

**Rs. in Lakh**

Sr. No	Particulars	STANDALONE					
		Quarter ended			Year to date figures for the period ended		Year ended
		31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from Operations	5,079.45	11,078.93	11,718.09	30,443.23	50,119.42	62,816.62
II	Other Income	89.96	95.52	378.12	355.19	1,047.00	1,303.62
III	Total Income (I+II)	5,169.41	11,174.45	12,096.21	30,798.42	51,166.42	64,120.24
IV	Expenses						
	Cost of materials consumed	4,317.12	7,238.22	11,102.36	23,631.98	38,434.36	46,083.46
	Changes in inventories of finished goods and work-in-progress	(785.23)	364.28	(4,130.33)	(2,236.66)	(6,934.54)	(5,959.03)
	Employee benefits expense	1,443.16	1,724.58	1,139.68	4,705.77	3,940.20	5,225.88
	Finance costs	609.95	599.84	588.38	1,856.47	1,433.51	2,074.01
	Depreciation and amortisation expense	871.79	917.31	881.08	2,729.14	2,593.72	3,371.19
	Other expenses	1,937.20	2,093.83	2,393.63	6,203.41	7,593.21	9,839.82
	Total expenses (IV)	8,393.99	12,938.06	11,974.80	36,890.11	47,060.46	60,635.33
V	Profit / (loss) before exceptional items and tax (III - IV)	(3,224.58)	(1,763.61)	121.41	(6,091.69)	4,105.96	3,484.91
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit / (loss) before tax (V-VI)	(3,224.58)	(1,763.61)	121.41	(6,091.69)	4,105.96	3,484.91
VIII	Tax Expense:						
	(1) Current tax	-	-	(158.83)	-	102.39	-
	(2) Deferred tax	(790.03)	(419.05)	197.45	(1,491.87)	952.00	932.87
IX	Profit / (loss) for the period/year from continuing operations (VII-VIII)	(2,434.55)	(1,344.56)	82.79	(4,599.82)	3,051.57	2,552.04
X	Profit / (loss) from discontinuing operations	-	-	-	-	-	-
XI	Tax expense of discontinuing operations	-	-	-	-	-	-
XII	Profit / (loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit / (loss) for the period/year (IX + XII)	(2,434.55)	(1,344.56)	82.79	(4,599.82)	3,051.57	2,552.04
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	(0.50)	(0.50)	(0.50)	(1.50)	(1.50)	(30.58)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.13	0.12	0.13	0.38	0.38	7.70
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period/year (XIII + XIV) (Comprising Profit / (loss) and Other Comprehensive Income for the period/year)	(2,434.92)	(1,344.94)	82.42	(4,600.94)	3,050.45	2,529.16
XVI	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,960.92	1,960.92	1,960.57	1,960.92	1,960.57	1,960.57
XVII	Other Equity excluding Revaluation Reserve						39,918.80
XVIII	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing & discontinuing operations) (non-annualised) :						
	(1) Basic (in Rs.)	(12.42)	(6.86)	0.42	(23.46)	15.57	13.02
	(2) Diluted (in Rs.)	(12.42)	(6.86)	0.42	(23.46)	15.56	13.02

Notes:

- 1 The above Financial Results which are published in accordance with Regulations 33 and Regulations 52 (4) read with regulation 63 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Thursday, 25th January, 2024.
- 2 The Financial Results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act, 2013 ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to limited review by the Statutory Auditors of the Company and they have expressed an unmodified review report.
- 3 The Company has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- 4 The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards employment and post-employment benefits. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its valuation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.

For Astec LifeSciences Limited

Anurag
Roy

Anurag Roy

Whole – Time Director & Chief Executive Officer

DIN : 07444595

Place : Mumbai

Date : 25th January, 2024

Digitally signed by Anurag Rg
DN: c=IN, o=Personal, title=S392,
pseudonym=297fab86897412d9fb65226dc5
2b0be,
2.5.4.20=a2c6a43bb74bb309d3c2e8d57b56c0
11f56c4722d0ffdc3b669873095720c965,
postalCode=500008, st=Telangana,
serialNumber=eefb19cac1bf08c37871890fac
6e2a9842d83b6504d831fe45ca48cf2969e,
cn=Anurag Rg
Date: 2024.01.25 15:57:36 +05'30'

BURJIS
TEHMURASP
PARDIWALA

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2024.01.25
16:13:27 +05'30'



Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236



Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecsls.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com

Additional disclosures as per Clause 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No	Particulars	STANDALONE					
		Quarter Ended			Year to date figures for the period ended		Year ended
		31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Current Ratio (refer note 1)	0.86	0.93	1.04	0.86	1.04	0.95
II	Net Worth (in Rs. Lakh)	37,013.99	39,441.61	42,394.08	37,013.99	42,394.08	41,879.37
III	Outstanding redeemable preference shares (quantity and value)	-	-	-	-	-	-
IV	Net profit after tax	(2,434.55)	(1,344.56)	82.79	(4,599.82)	3,051.57	2,552.04
V	Basic Earnings per share	(12.42)	(6.86)	0.42	(23.46)	15.57	13.02
VI	Diluted Earnings per share	(12.42)	(6.86)	0.42	(23.46)	15.56	13.02
VII	Capital Redemption Reserve (in Rs. Lakh)	0.30	0.30	0.30	0.30	0.30	0.30
VIII	Debt Equity ratio (refer note 1)	1.23	1.09	0.87	1.23	0.87	0.81
IX	Debt Service Coverage Ratio (DSCR) (refer note 1)	(0.47)	0.09	2.50	# (0.00)	1.27	1.25
X	Interest Service Coverage Ratio (ISCR) (refer note 1)	(1.56)	0.29	2.63	# (0.00)	4.90	3.88
XI	Long term debt to working capital (refer note 1)	*	16.74	0.84	*	0.84	3.33
XII	Bad debts to Account receivable ratio (refer note 1)	-	-	-	-	-	-
XIII	Current liability ratio (refer note 1)	0.69	0.66	0.95	0.69	0.95	0.86
XIV	Total debts to total assets (refer note 1)	0.50	0.47	0.37	0.50	0.37	0.35
XV	Debtors turnover (refer note 1)	2.31	3.25	2.35	3.50	2.88	2.75
XVI	Inventory turnover (refer note 1)	0.91	1.90	2.00	1.54	2.96	2.61
XVII	Operating margin (%)	-36.08%	-3.09%	10.30%	-6.11%	14.10%	12.14%
XVIII	Net profit margin (%)	-47.93%	-12.14%	0.70%	-15.11%	6.10%	4.06%

*Net working Capital is negative

Amount is below rounding off two decimal

- 1 Pursuant to SEBI Operational Circular for Issue and Listing of Non-Convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper dated 10th August, 2021, the Company has listed Commercial Papers on National Stock Exchange (NSE).

The Company is rated by leading credit agency ICRA and India Ratings & Research. ICRA has assigned the rating "[ICRA] A1+" and "[ICRA] AA-" for its short term facilities (including commercial paper) and long term facilities respectively. India Ratings & Research has assigned "[IND] AA-" for its Non- Convertible Debentures (NCDs).

Formulae for computation of ratios:

Current ratio : Current assets / Current liabilities

Net Worth: Total equity

Debt Equity ratio : Total Debt / Shareholder's Equity

Debt Service Coverage Ratio : (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / (Interest & Lease Payments + Principal Repayments)

Interest service coverage ratio: (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / Interest expense

Long term debt to working capital : (Non-current borrowings+Current maturities of long term debt) / (Current Assets - (Current liabilities-Current maturities of long term debt))

Bad debts to Account receivable ratio : Bad debts including provision for doubtful debts / Average Trade receivable.

Current liability ratio : (Current liabilities-Current maturities of Long term Debt) / Total liabilities

Total debts to total assets : Total borrowings / Total assets

Debtors turnover : Net Credit Sales / Average Trade Receivable (Opening balance+Closing balance/2) (annualised)

Inventory turnover : Net Sales/ Average Inventory (Opening Balance+ Closing balance/2) (annualised).

Operating margin (%): Earnings before Interest, Tax & Depreciation & Amortisation less Other Income/Revenue from Operations

Net Profit/Loss margin(%): Profit/Loss after Tax(after exceptional items)/Revenue from Operations

Anurag
Roy

Digitally signed by Anurag Roy
DN: cn=Anurag Roy, email=anurag.roy@astecsls.com, o=Astec Life Sciences Limited, ou=Finance, postalCode=400079, st=Maharashtra, serialNumber=1, c=IN
Date: 2024.01.25 15:58:19 +05'30'

BURJIS
TEHMURASP
PARDIWALA

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2024.01.25
16:13:55 +05'30'

Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com

Statement of Unaudited Consolidated Financial Results for the Quarter and Nine Months ended 31st December, 2023



Rs. In Lakh

Sr. No	Particulars	CONSOLIDATED					
		Quarter Ended			Year to date figures for the period ended		Year ended
		31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from Operations	5,079.45	11,078.93	11,718.09	30,443.23	50,119.42	62,816.62
II	Other Income	90.93	97.88	378.88	359.67	1,048.51	1,306.01
III	Total Income (I+II)	5,170.38	11,176.81	12,096.97	30,802.90	51,167.93	64,122.63
IV	Expenses						
	Cost of materials consumed	4,317.11	7,238.23	11,102.36	23,631.98	38,434.36	46,083.44
	Changes in inventories of finished goods and work-in-progress	(785.23)	364.28	(4,130.33)	(2,236.66)	(6,934.54)	(5,959.03)
	Employee benefits expense	1,443.16	1,724.58	1,139.68	4,705.77	3,940.20	5,225.88
	Finance costs	609.49	599.38	587.74	1,855.09	1,431.58	2,071.43
	Depreciation and amortisation expense	870.31	915.81	879.59	2,724.67	2,589.25	3,365.25
	Other expenses.	1,937.50	2,094.10	2,393.91	6,204.26	7,594.03	9,840.93
	Total expenses (IV)	8,392.34	12,936.38	11,972.95	36,885.11	47,054.88	60,627.89
V	Profit / (loss) before exceptional items and tax (III - IV)	(3,221.96)	(1,759.57)	124.02	(6,082.21)	4,113.05	3,494.73
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit / (loss) before tax (V-VI)	(3,221.96)	(1,759.57)	124.02	(6,082.21)	4,113.05	3,494.73
VIII	Tax Expense:						
	(1) Current tax	0.78	1.11	(158.12)	2.70	104.32	2.67
	(2) Deferred tax	(790.14)	(419.15)	197.41	(1,492.19)	951.86	932.67
IX	Profit / (loss) for the period/year from continuing operations (VII-VIII)	(2,432.60)	(1,341.53)	84.73	(4,592.72)	3,056.87	2,559.40
X	Profit / (loss) from discontinuing operations						-
XI	Tax expense of discontinuing operations						-
XII	Profit / (loss) from discontinuing operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit / (loss) for the period/year (IX + XII)	(2,432.60)	(1,341.53)	84.73	(4,592.72)	3,056.87	2,559.40
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	(0.50)	(0.50)	(0.50)	(1.50)	(1.50)	(30.58)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.13	0.12	0.13	0.38	0.38	7.70
	B (i) Items that will be reclassified to profit or loss	(0.49)	(1.17)	0.27	(1.65)	1.15	1.06
	(ii) Income tax relating to items that will be reclassified to profit or loss						
	Total Comprehensive Income for the period/year (XIII + XIV)	(2,433.46)	(1,343.08)	84.63	(4,595.49)	3,056.91	2,537.58
XV	(Comprising Profit / (loss) and Other Comprehensive Income for the period/year)						
XVI	Net Profit/(loss) attributable to:						
	- Owners	(2,433.42)	(1,342.70)	83.97	(4,595.57)	3,054.78	2,556.49
	- Non controlling interests	0.82	1.17	0.76	2.85	2.09	2.90
	Total Comprehensive Income attributable to:						
	- Owners	(2,434.28)	(1,344.25)	83.88	(4,598.34)	3,054.82	2,534.67
	- Non controlling interests	0.82	1.17	0.76	2.85	2.09	2.90
XVII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	1,960.92	1,960.92	1,960.57	1,960.92	1,960.57	1,960.57
XVIII	Other Equity excluding Revaluation Reserve						39,975.75
XIX	Earnings per equity share (Face Value of Rs.10/- per share) (for continuing & discontinuing operations) (non-annualised) :						
	(1) Basic (in Rs.)	(12.41)	(6.85)	0.43	(23.44)	15.58	13.04
	(2) Diluted (in Rs.)	(12.41)	(6.85)	0.43	(23.44)	15.58	13.04

Notes:

- The above Financial Results which are published in accordance with Regulations 33 and Regulations 52 (4) read with regulation 63 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its Meeting held on Thursday, 25th January, 2024.
- The Financial Results are in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act, 2013 ("Act"), read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (including any amendment(s) / modification(s) / re-enactment(s) thereto). The Financial Results have been subjected to limited review by the Statutory Auditors of the Company and they have expressed an unmodified review report.
- The Group has only one reportable segment i.e. Agrochemicals as per Ind-AS 108 "Operating Segments" specified under Section 133 of the Companies Act, 2013.
- The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards employment and post-employment benefits. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Group will assess the impact and its valuation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.

For Astec LifeSciences Limited

Anurag Roy

Anurag Roy

Digitally signed by Anurag Roy
DN: c=IN, o=Personal, title=S392,
pseudonym=297fab8d6897412d9b65226
dc5200be,
2.5.4.20=a2c6a3bb74bb309d3c2e8d57b5
4e01f56c4722dfdc3dc669873095720c96
5, postalCode=500008, st=Telangana,
serialNumber=eebf19cac10f08a3c7871890
fadc2a08428d836504bee31fe45ac4bfc2
969c, cn=Anurag Roy
Date: 2024.01.25 15:59:06 +05'30'

**BURJIS
TEHMURASP
PARDIWALA**

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2024.01.25
16:14:16 +05'30'

Whole – Time Director & Chief Executive Officer

DIN : 07444595

Place : Mumbai

Date : 25th January, 2024



Astec LifeSciences Limited

Corporate Identity Number : L99999MH1994PLC076236

Registered Office : Godrej One, 3rd Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (East), Mumbai- 400079, Maharashtra

Website: www.astecsl.com, Tel no.: 022-2519 5768, Fax no.: 022-2261 8289, Email id: astecinvestors@godrejastec.com



Additional disclosures as per Clause 52(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No	Particulars	CONSOLIDATED					
		Quarter Ended			Year to date figures for the period ended		Year ended
		31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Current Ratio (refer note 1)	0.86	0.93	1.04	0.86	1.04	0.95
II	Net Worth (in Rs. Lakh)	37,073.55	39,500.50	42,449.88	37,073.55	42,449.88	41,936.32
III	Outstanding redeemable preference shares (quantity and value)	-	-	-	-	-	-
IV	Net profit after tax	(2,432.60)	(1,341.53)	84.73	(4,592.72)	3,056.87	2,559.40
V	Basic Earnings per share	(12.41)	(6.85)	0.43	(23.44)	15.58	13.04
VI	Diluted Earnings per share	(12.41)	(6.85)	0.43	(23.44)	15.58	13.04
VII	Capital Redemption Reserve (in Rs. Lakh)	0.30	0.30	0.30	0.30	0.30	0.30
VIII	Debt Equity ratio (refer note 1)	1.23	1.09	0.87	1.23	0.87	0.81
IX	Debt Service Coverage Ratio (DSCR) (refer note 1)	(0.47)	0.10	2.52	# (0.00)	1.27	1.25
X	Interest Service Coverage Ratio (ISCR) (refer note 1)	(1.56)	0.29	2.63	# (0.00)	4.90	3.89
XI	Long term debt to working capital (refer note 1)	*	15.09	0.83	*	0.83	3.16
XII	Bad debts to Account receivable ratio (refer note 1)	0.00	0.00	-	0.00	-	0.00
XIII	Current liability ratio (refer note 1)	0.69	0.66	0.95	0.69	0.95	0.86
XIV	Total debts to total assets (refer note 1)	0.49	0.47	0.37	0.49	0.37	0.35
XV	Debtors turnover (refer note 1)	2.31	3.25	2.35	3.50	2.88	2.75
XVI	Inventory turnover (refer note 1)	0.91	1.90	2.00	1.54	2.96	2.61
XVII	Operating margin (%)	-36.09%	-3.09%	10.30%	-6.12%	14.10%	12.14%
XVIII	Net profit margin (%)	-47.89%	-12.11%	0.70%	-15.09%	6.10%	4.07%

*Net Working Capital is negative

Amount is below rounding off two decimal

- 1 Pursuant to SEBI Operational Circular for Issue and Listing of Non-Convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper dated 10th August, 2021, the Company has listed Commercial Papers on National Stock Exchange (NSE).

The Company is rated by leading credit agency ICRA and India Ratings & Research. ICRA has assigned the rating "[ICRA] A1+" and "[ICRA] AA-" for its short term facilities (including commercial paper) and long term facilities respectively. India Ratings & Research has assigned "[IND] AA-" for its Non-Convertible Debentures (NCDs).

Formulae for computation of ratios:

Current ratio : Current assets / Current liabilities

Net Worth: Total equity

Debt Equity ratio : Total Debt / Shareholder's Equity

Debt Service Coverage Ratio : (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / (Interest & Lease Payments + Principal Repayments)

Interest service coverage ratio: (Net Profit after taxes + Non-cash operating expenses like depreciation and other amortizations + Interest + other adjustments like loss on sale of Fixed assets/Investment etc.) / Interest expense

Long term debt to working capital : (Non-current borrowings+Current maturities of long term debt) / (Current Assets - (Current liabilities-Current maturities of long term debt))

Bad debts to Account receivable ratio : Bad debts including provision for doubtful debts / Average Trade receivable.

Current liability ratio : (Current liabilities-Current maturities of Long term Debt) / Total liabilities

Total debts to total assets : Total borrowings / Total assets

Debtors turnover : Net Credit Sales / Average Trade Receivable (Opening balance+Closing balance/2) (annualised)

Inventory turnover : Net Sales/ Average Inventory (Opening Balance+ Closing balance/2) (annualised).

Operating margin (%): Earnings before Interest, Tax & Depreciation & Amortisation less Other Income/Revenue from Operations

Net Profit/ Loss margin(%): Profit/Loss after Tax(after exceptional items)/Revenue from Operations

Anura
g Roy

Digitally signed by Anurag Roy
DN: cn=IN, o=Personal, title=5392,
pseudonym=297fab9d6897412d9fb65226
dc52b0be,
2.5.4.20=a2c6a43bb74bb309d3c2e8d57b5
4c011f56c4722dfdc3dc669873095720c96
5, postalCode=500008, st=Telangana,
serialNumber=eebf19cac1bf08e3c787189
0fac6e2a98428d836504bee31fe45ac4becf
2969e, cn=Anurag Roy
Date: 2024.01.25 16:00:06 +05'30'

BURJIS
TEHMURASP
PARDIWALA

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2024.01.25
16:14:31 +05'30'

Limited Review Report on unaudited standalone financial results of Astec LifeSciences Limited for the quarter ended 31 December 2023 and year to date results for the period from 1 April 2023 to 31 December 2023 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021

To the Board of Directors of Astec LifeSciences Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Astec LifeSciences Limited (hereinafter referred to as “the Company”) for the quarter ended 31 December 2023 and year to date results for the period from 1 April 2023 to 31 December 2023 (“the Statement”).
2. This Statement, which is the responsibility of the Company’s management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, including the manner in which it is to be disclosed, or that it contains any

B S R & Co. LLP

Limited Review Report (Continued)

Astec LifeSciences Limited

material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

BURJIS
TEHMURASP
PARDIWALA

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2024.01.25
16:15:01 +05'30'

Burjis Pardiwala

Partner

Mumbai

25 January 2024

Membership No.: 103595

UDIN:24103595BKFWEH5042

Limited Review Report on unaudited consolidated financial results of Astec LifeSciences Limited for the quarter ended 31 December 2023 and year to date results for the period from 1 April 2023 to 31 December 2023 pursuant to Regulation 33 and Regulation 52(4) read with Regulation 63 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021

To the Board of Directors of Astec LifeSciences Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Astec LifeSciences Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 31 December 2023 and year to date results for the period from 1 April 2023 to 31 December 2023 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"), as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021.
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities mentioned in Annexure I to the Statement:
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52(4) read with Regulation 63 of the Listing Regulations, as prescribed in Securities and Exchange Board of India operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Registered Office:

Limited Review Report (Continued)

Astec LifeSciences Limited

6. We did not review the interim financial information of one Subsidiary included in the Statement, whose interim financial information reflect total revenues (before consolidation adjustments) of Rs.3.66 lakhs and Rs.12.57 lakhs, total net profit / (loss) after tax (before consolidation adjustments) of Rs.2.36 lakhs and Rs.8.28 lakhs and total comprehensive income (before consolidation adjustments) of Rs.2.36 lakhs and Rs 8.28 lakhs, for the quarter ended 31 December 2023 and for the period from 1 April 2023 to 31 December 2023 respectively, as considered in the Statement. These interim financial information has been reviewed by other auditor whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

7. The Statement includes the interim financial information of one Subsidiary which have not been reviewed, whose interim financial information reflect total revenues (before consolidation adjustments) of Rs .Nil and Rs.Nil, total net profit / (loss) after tax (before consolidation adjustments) of Rs.Nil and Rs.Nil and total comprehensive income (before consolidation adjustments) of Rs.Nil and Rs.Nil , for the quarter ended 31 December 2023 and for the period from 1 April 2023 to 31 December 2023 respectively, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

BURJIS
TEHMURASP
PARDIWALA

Digitally signed by
BURJIS TEHMURASP
PARDIWALA
Date: 2024.01.25
16:15:29 +05'30'

Burjis Pardiwala

Partner

Mumbai

25 January 2024

Membership No.: 103595

UDIN:24103595BKFWEI8085

Limited Review Report (Continued)**Astec LifeSciences Limited****Annexure I**

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Astec LifeSciences Limited	Holding Company
2	Behram Chemicals Private Limited	Subsidiary Company
3	Comercializadora Agricola Agroastrachem Cia Ltda	Subsidiary Company